U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07253324) titled 'ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)' on Nov. 19.
Brief Summary: The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ENX-104 in participants with major depressive disorder with anhedonia (aMDD).
Study Start Date: Feb. 17
Study Type: INTERVENTIONAL
Condition:
Major Depressive Disorder
Intervention:
DRUG: ENX-104
Oral Solution
DRUG: Placebo
Oral solution
Recruitment Status: RECRUITING
Sponsor: Engrail Therapeutics INC
Disclaimer: Curated by HT Syndication....